Methods of extending corneal graft survival
CA 2476994 A1 · Owner: Allergan, Inc. · Inventors: De Vries, Gerlad W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method of extending corneal graft survival following corneal transplantation in a patient by administering to the patient an effective amount of a pharmaceutical composition containing a vascular endothelial growth factor receptor-3 (VEGFR-3) inhibitor whereby , lymphangiogenesis is suppressed in the cornea of the patient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.